Inhibikase Therapeutics Future Growth
Future criteria checks 0/6
Inhibikase Therapeutics is forecast to grow earnings and revenue by 35.2% and 80.8% per annum respectively while EPS is expected to grow by 48.1% per annum.
Key information
35.2%
Earnings growth rate
48.1%
EPS growth rate
Biotechs earnings growth | 34.4% |
Revenue growth rate | 80.8% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 15 Aug 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 9 | -26 | N/A | -23 | 2 |
12/31/2025 | N/A | -27 | N/A | -21 | 2 |
12/31/2024 | N/A | -20 | N/A | -19 | 2 |
6/30/2024 | 0 | -18 | -16 | -16 | N/A |
3/31/2024 | 0 | -19 | -16 | -16 | N/A |
12/31/2023 | 0 | -19 | -18 | -18 | N/A |
9/30/2023 | 0 | -19 | -18 | -18 | N/A |
6/30/2023 | 0 | -19 | -20 | -20 | N/A |
3/31/2023 | 0 | -18 | -20 | -19 | N/A |
12/31/2022 | 0 | -18 | -18 | -17 | N/A |
9/30/2022 | 0 | -19 | -18 | -18 | N/A |
6/30/2022 | 0 | -19 | -14 | -14 | N/A |
3/31/2022 | 2 | -17 | -14 | -14 | N/A |
12/31/2021 | 3 | -15 | -14 | -14 | N/A |
9/30/2021 | 3 | -11 | -11 | -11 | N/A |
6/30/2021 | 3 | -7 | -9 | -9 | N/A |
3/31/2021 | 2 | -5 | -5 | -5 | N/A |
12/31/2020 | 1 | -3 | -1 | -1 | N/A |
9/30/2020 | 1 | -2 | 0 | 0 | N/A |
6/30/2020 | 1 | -3 | 0 | 0 | N/A |
3/31/2020 | 1 | -5 | 0 | 0 | N/A |
12/31/2019 | 1 | -6 | 0 | 0 | N/A |
9/30/2019 | 2 | -7 | 1 | 1 | N/A |
3/31/2019 | 4 | -4 | 0 | 0 | N/A |
12/31/2018 | 4 | -2 | 1 | 1 | N/A |
9/30/2018 | 3 | -1 | 0 | 0 | N/A |
3/31/2018 | 3 | 0 | N/A | 0 | N/A |
12/31/2017 | 2 | 0 | N/A | 0 | N/A |
12/31/2016 | 1 | -1 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IQT0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IQT0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IQT0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IQT0 is forecast to have no revenue next year.
High Growth Revenue: IQT0 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IQT0's Return on Equity is forecast to be high in 3 years time